Female Contraception - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Female Contraception - Pipeline Review, H1 2016’, provides an overview of the Female Contraception pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Female Contraception
- The report reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Female Contraception therapeutics and enlists all their major and minor projects
- The report assesses Female Contraception therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Female Contraception
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Female Contraception
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Female Contraception pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Female Contraception Overview 8
Therapeutics Development 9
Pipeline Products for Female Contraception - Overview 9
Pipeline Products for Female Contraception - Comparative Analysis 10
Female Contraception - Therapeutics under Development by Companies 11
Female Contraception - Therapeutics under Investigation by Universities/Institutes 12
Female Contraception - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Female Contraception - Products under Development by Companies 16
Female Contraception - Products under Investigation by Universities/Institutes 17
Female Contraception - Companies Involved in Therapeutics Development 18
Agile Therapeutics, Inc. 18
ANI Pharmaceuticals, Inc. 19
Evofem, Inc. 20
Mithra Pharmaceuticals S.A. 21
Orbis Biosciences, Inc. 22
Female Contraception - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(drospirenone + estetrol) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
(estradiol acetate + nestorone) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
(estradiol acetate + prasterone + progesterone) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
AG-200 ER - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AG-200 SP - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AG-20015 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Amphora - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
etonogestrel ER - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
EVE-106 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
levonorgestrel - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
LJ-102 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Monoclonal Antibody Conjugates for Contraception - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NOV-1003 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
S-003296 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
S-0101255 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule 1 for Fertility Control - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule 2 for Fertility Control - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Synthetic Peptides for Contraception - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Female Contraception - Dormant Projects 60
Female Contraception - Discontinued Products 62
Female Contraception - Product Development Milestones 63
Featured News & Press Releases 63
Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies 63
Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone 63
Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study 64
Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 64
Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 65
Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive 65
Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial 66
Aug 26, 2015: The European Journal Of Contraception And Reproductive Health Care Publishes Two Scientific Articles About E4 (Estetrol) Dinox Phase II Study: Two Of The Most Read Papers By The Scientific Community 67
Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive 68
Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive 68
Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 69
Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 69
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 69
Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 70
Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73
List Of Tables
List of Tables
Number of Products under Development for Female Contraception, H1 2016 9
Number of Products under Development for Female Contraception - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Female Contraception - Pipeline by Agile Therapeutics, Inc., H1 2016 18
Female Contraception - Pipeline by ANI Pharmaceuticals, Inc., H1 2016 19
Female Contraception - Pipeline by Evofem, Inc., H1 2016 20
Female Contraception - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 21
Female Contraception - Pipeline by Orbis Biosciences, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Assessment by Combination Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Female Contraception - Dormant Projects, H1 2016 60
Female Contraception - Dormant Projects (Contd..1), H1 2016 61
Female Contraception - Discontinued Products, H1 2016 62
List Of Figures
List of Figures
Number of Products under Development for Female Contraception, H1 2016 9
Number of Products under Development for Female Contraception - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 23
Assessment by Combination Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
